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mented with regional cerebral perfusion may provide better
cerebral protection than more conventional techniques.
Although the data presented by Pigula, Siewers, and
Nemoto are suggestive of adequate cerebral protection, we
still believe that core cooling to 18°C is the principal compo-
nent of our cerebral protection strategy. Further study is war-
ranted to ascertain the relative merits of regional cerebral per-
fusion versus hypothermia for cerebral protection during
aortic arch reconstruction in the neonate. 
Christopher A. Caldarone, MD
Douglas M. Behrendt, MD
Division of Cardiovascular Surgery
Children’s Hospital of Iowa
200 Hawkins Dr
Iowa City, IA 52242-1083
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Drug therapy before coronary artery operations
To the Editor:
We were greatly interested by the results of the IMAGE
trial,1 which suggests European patients are more susceptible
than US patients to aprotinin-induced vein graft occlusion.
This has prompted us to inquire whether our patients have a
European or US response to aprotinin.
We have used aprotinin in varying doses for patients under-
going redo operations or for those with recent aspirin inges-
tion. Table I describes our mortality rate in consecutive
patients undergoing coronary artery bypass grafting with or
without other procedures between 1993 and 1998; a dose-
dependent increase in mortality is evident. However, the indi-
cations for aprotinin are also very important risk factors for
perioperative mortality. Thus it may not be too surprising that
patients given aprotinin have a higher mortality rate. To clar-
ify this, we have further analyzed our data to take risk factors
for mortality into account.
The patients and model have been described in detail else-
where.2 Logistic regression was performed with in-hospital
mortality from any cause as the dependent factor and 22 inde-
pendent factors: age, sex, urgency of the operation, history of
cardiac surgery, concurrent cardiac or cardiovascular proce-
dures, left ventricular function, recent myocardial infarct, left
main coronary artery stenosis, chronic airways disease, cere-
brovascular disease, diabetes, hypertension, and other risk
factors including preoperative cardioactive drug use.
Stepwise regression was not used.
In this model we found the relative risk of mortality attrib-
utable to aprotinin to be 1.34 per million units of aprotinin
with 95% confidence intervals of 1.1 to 1.7 (P = .01 for rela-
tive risk = 1). This indicates a risk-adjusted association
between aprotinin and in-hospital mortality.
In the jargon of evidence-based medicine, our data are
“class III evidence” and should not be considered conclusive.
However, taken in conjunction with the IMAGE trial results,
our data support the hypothesis that in some circumstances
aprotinin may have a deleterious effect on patients undergo-
ing coronary artery operations.
We do not understand why aprotinin appears to have
adverse effects in some surgical units and not others. We use
balanced salt solutions for vein distention, maintain kaolin-
activated clotting times above 600 seconds, and never admin-
ister our blood cardioplegic solution through vein grafts.
Until it becomes clear why the adverse effects of aprotinin
appear to be site specific, we would suggest that aprotinin
should be used with caution in coronary artery operations.
William M. Weightman, MB, ChB
M. A. J. Newman, MD
Departments of Anesthesia and Cardiac Surgery
Sir Charles Gairdner Hospital
Verdun St
Nedlands 6009, Australia
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Reply to the Editor:
The letter by Weightman and Newman suggests a dose-
dependant mortality for aprotinin doses ranging from 0 to
‡ 4,000,000 KIU (see their Table I). In the IMAGE study (J
Thorac Cardiovasc Surg 1998;116:716-30), the average dose
in aprotinin-treated patients was 5,550,000 KIU (n = 436).
This total includes the 2,000,000 KIU loading dose,
2,000,000 KIU into the cardiopulmonary bypass circuit
prime, plus 1,570,000 KIU by continuous infusion at a pre-
scribed rate of 500,000 KIU per hour. IMAGE study results
showed that this administration regimen for aprotinin had no
effect on mortality (placebo, 1.6%; aprotinin, 1.4%). In the
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 5
Letters to the Editor   979
Table I. Dose of aprotinin, number of patients, and
in-hospital mortality rate for 1593 consecutive
patients undergoing coronary artery operations
Dose of aprotinin Mortality rate 
(106 KIU) n (%)
0 839 1.8
<1 248 3.2
1-1.9 191 3.1
2-2.9 201 6.5
3-3.9 62 9.7
‡ 4 52 11.5
IMAGE study, 7 hospital deaths occurred in 434 placebo-
treated patients (1.6%). This is similar to the 1.8% hospital
mortality reported for non-aprotinin treated patients by
Weightman and Newman. However, aprotinin-treated
patients in the IMAGE study had a substantially lower hospi-
tal mortality than those patients treated with a comparable
dose (‡ 4,000,000 KIU) in Weightman and Newman’s letter:
1.4% compared with 11.5%.
Weightman and Newman report that of 754 patients receiv-
ing aprotinin, 93% received less than 4,000,000 KIU of apro-
tinin (see their Table I). Their reporting of the total dose
makes unclear the administration regimen (ie, pump only,
half dose, or full dose, as in the IMAGE study) and timing
(from the beginning of the operation, as recommended, or,
perhaps, after loss of hemostasis). Furthermore, and with the
exception of pump-only administration, aprotinin is typically
administered as a constant infusion per hour. In the simplest
scenario (no pump or loading dose), any differences in the
amount of aprotinin administered would result wholly from
the length of the operation. 
The variables that separated European from US patients in the
IMAGE study were primarily related to adverse angiographic
characteristics of the recipient vessels in addition to female sex,
older age, prior aspirin use, and abnormal left ventricular ejec-
tion fraction. The only predictor variables in the IMAGE study
for which there are data in Weightman and Newman’s patient
population (Anesth Analg 1999;88:286-91) are age, sex, and
aspirin use. Their patients were older than those in the IMAGE
study (63.8 years compared with 61.6 years at US sites and 62.0
years at Danish and Israeli sites), had a higher proportion of
women (20.5% compared with 9.4% at US sites and 14.3% at
Danish and Israeli sites), and a higher proportion of aspirin
users (58.8% compared with 42.8% at US sites and 26.1% at
Danish and Israeli sites). In the IMAGE study, aspirin use was
associated with a lower risk of graft occlusion, whereas the
other 2 variables, sex and age, were consistent with patients
having a higher risk for vein graft occlusion. Comparative data
on Weightman and Newman’s patient characteristics are too
limited to determine whether responses are more similar to
those observed in our European or US patient populations. It is
also unclear whether Weightman and Newman’s data are
prospective or retrospective.
These differences suggest that patients in Weightman and
Newman’s population—and particularly those receiving
aprotinin—had a more adverse patient profile than either US
or European patients in the IMAGE study or there were other
technical differences in the surgical procedures. Thus infer-
ences should not be made from a nonrandomized study, par-
ticularly one with apparent treatment biases.
Edwin L. Alderman, MD
For the IMAGE Investigators
Division of Cardiovascular Medicine
Stanford University School of Medicine
Falk Cardiovascular Research Center
CV-261, 300 Pasteur Dr
Stanford CA 94305-5406
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Abciximab (ReoPro) removal with a hemoconcen-
trator during cardiopulmonary bypass 
To the Editor:
The problem of performing emergency cardiac surgery on
patients who have been recently treated with abciximab
(ReoPro, Eli Lilly and Company, Indianapolis, Ind) as
addressed by Poullis and associates1 is indeed of considerable
interest to surgeons. The in vitro experiment they described,
however, may have limited applicability to the clinical situa-
tion of operating on a patient who has been recently treated
with abciximab. In their method, abciximab was added to a
solution of saline and then subjected to hemoconcentration
during circulation in an in vitro cardiopulmonary bypass cir-
cuit. However, platelets were not included in the test solution.
This protocol is quite different from the situation of a patient
who has been recently treated with abciximab and who does
have platelets.
Poullis and associates state that the purpose of hemofiltra-
tion is to remove free abciximab so that subsequently admin-
istered donor platelets will have the role of providing hemo-
stasis rather than “primarily absorbing free antibody.” This
hypothesis, however, is not consistent with the pharmacody-
namic profile of abciximab.
When abciximab is administered, the drug rapidly
binds to the platelet glycoprotein IIb/IIIa receptors and
results in severe inhibition of platelet aggregation and pro-
longation of the bleeding time.2,3 The binding of abciximab
to the platelets is noncompetitive and the dissociation rate
from platelets is slow. Excess non-bound abciximab is
rapidly cleared, and within 30 minutes of abciximab ad-
ministration less than 4% of the administered dose is pre-
sent within the serum as free antibody.4 Thus essentially no
abciximab is available for removal by hemofiltration.
Likewise, when donor platelets are transfused, no free
abciximab is present to be “absorbed.” When platelets are
transfused there is, however, redistribution of abciximab
from native (bound) platelet receptors to transfused (un-
bound) platelet receptors, resulting in an overall reduction
in the percentage of bound receptors. When this overall
percentage of blocked receptors falls below approximately
80%, the bleeding time and hemostasis return toward nor-
mal. This is the rationale for transfusing platelets to reverse
the effect of abciximab.3,4
Potential methods to reduce the bleeding diathesis in
patients requiring surgery while under the effect of abcix-
imab are welcome to surgeons who have to deal with this
problem. At present, however, platelet administration to
dilute the abciximab blockade of the platelet glycoprotein
IIb/IIIa receptors would appear to be the antidote of choice.
My colleagues and I5 recently reported experience with 12
patients who required emergency coronary artery bypass
grafting shortly after abciximab treatment. The routine
transfusion of 1 apheresis platelet unit (volume equal to 6
random donor platelets but acquired from a single donor)
after reversal of heparin effect by protamine, with addition-
980 Letters to the Editor The Journal of Thoracic and
Cardiovascular Surgery
November 1999
